Evidence map›Paper›PMID 38974707›Full record

ArticleClinical, cosmetic and investigational dermatology2024

Combination of a Topical Anti-Inflammatory Drug and a Moisturizer, Both with a Lamellar Structure Containing Synthetic Pseudo-Ceramides, for the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.

Keita Okoshi, Shotaro Ito, Megumi Matsuoka, Yoshinori Kinugasa, Eri Shimizu, Kosei Tanaka, Joji Okada, Takahiro Nishizaka, Azumi Nagasawa, Tsuyoshi Seki and 3 more

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Keita OkoshiHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Shotaro ItoHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.ORCID 0000-0002-4836-284X
Megumi MatsuokaHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Yoshinori KinugasaHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Eri ShimizuAnalytical Science Research, Kao Corporation, Tochigi, Japan.
Kosei TanakaAnalytical Science Research, Kao Corporation, Tochigi, Japan.
Joji OkadaSkin Care Products Research, Kao Corporation, Tokyo, Japan.
Takahiro NishizakaHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Azumi NagasawaHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Tsuyoshi SekiHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Makoto IijimaHuman Health Care Products Research, Kao Corporation, Tokyo, Japan.
Masatoshi AbeSapporo Skin Clinic, Sapporo, Japan.
Osamu NemotoSapporo Skin Clinic, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Atopic dermatitis is characterized by chronic inflammation and dryness accompanied by severe itching. The combined use of moisturizers and topical anti-inflammatory drugs is essential for alleviating atopic dermatitis. We have developed a topical anti-inflammatory drug with a steroid and a moisturizer with heparinoid, both in lamellar structure-based formulations containing synthetic pseudo-ceramides. Here, assessed the efficacy of this combination in the treatment of atopic dermatitis. Methods: We included 22 patients with mild to moderate atopic dermatitis and subjected them to a seven-week treatment with the test formulations, followed by a four-week post-treatment period. Results: Clinical findings and the quality of life of participants remarkably improved after one week of treatment. Furthermore, skin hydration and transepidermal water loss considerably improved at weeks one and three, respectively. The Cer [NP]/[NS] ratio, an indicator of epidermal turnover, substantially increased during the treatment period and remained elevated even thereafter. The improvement in stratum corneum function was distinctive in participants with lower barrier function. Conclusion: These findings indicated that the combined use of the anti-inflammatory drug and moisturizer, both in lamellar structure-based formulations, is effective in treating atopic dermatitis in patients with fragile barrier function.

Indexed as

barrier functionbase formulationsheparinoidlamellar structuresteroidTEWL

Identifiers

PMID38974707
PMCPMC11227832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.